Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT03202147
Other study ID # AZT-003
Secondary ID
Status Withdrawn
Phase Phase 2
First received
Last updated
Start date December 2023
Est. completion date December 2024

Study information

Verified date April 2020
Source AZTherapies, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a Phase II, randomized, double-blinded, placebo-controlled study for subjects with evidence of PSCI.


Description:

This Phase II study is designed as a randomized, double-blinded, placebo-controlled study for subjects with evidence of PSCI. Subjects will be randomly assigned to the Group I arm (ALZT-OP1a adjuvant treatment), which will consist of ALZT-OP1a for inhalation, taken twice daily (morning and evening), OR the Group II placebo arm, which will consist of inhaled placebo, taken twice daily (morning and evening). A minimum of 350 subjects will be randomized to receive one of two possible treatment assignments: ALZT-OP1a adjuvant treatment of active study drug or placebo. To account for subject dropouts (estimated rate of 30%), it is anticipated that up to 500 (or 250 subjects per treatment arm) may be recruited and randomized, to achieve a minimum of 175 evaluable subjects per treatment arm. Randomization assignments will be stratified by site to ensure balance by site.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date December 2024
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria - Male or female, aged 18 years or above; - Subject has suffered a recent (within 1-7 days) ischemic stroke supported by CT scan or MRI findings; - Subject has a score on the NIHSS of 5-14 (inclusive); - Evidence of stroke related cognitive impairment, documented by neuropsychological evaluation and a Clinical Dementia Rating (Global) = 0.5; - Must be fluent in the language of the cognitive testing material being administered; - Study partner is available who has frequent contact with the participant (e.g. an average of 10 hours per week or more), and can accompany the participant to all clinic visits for the duration of the protocol; - Visual and auditory acuity adequate for neuropsychological testing. Exclusion Criteria: - Subject has medical history of dementia (prior to current ischemic stroke event); - Subject has a known medical history of major depression or psychotic disorder; - Unstable cardiovascular or cerebrovascular disease; - Aphasia or other disability severe enough to prevent valid neuropsychiatric assessment; - History of any other significant neurological disease prior to ischemic stroke; - History of schizophrenia or bipolar disorder (DSM-IV criteria); - History of alcohol or substance abuse or dependence within the past 3 years (DSM-IV criteria); - Currently taking medications that could lead to difficulty complying with the protocol; - Investigational agents are prohibited one month prior to entry and for the duration of the trial; - Currently taking cromolyn, or has taken cromolyn, within the past 12 months; - Allergy to cromolyn (also known as Intal®, Nasalcrom®, Opticrom®, Gastrocrom®, etc.); - Clinically significant respiratory disorders with impaired respiratory effort or difficulty taking inhaled drugs (examples: Stage III-IV chronic obstructive pulmonary disease [COPD], emphysema); - Uncontrolled chronic asthma; - Taking inhaled protein products on a chronic basis (such as insulin, parathyroid hormone [PTH], etc.); - Any significant systemic illness or unstable medical condition which could lead to difficulty complying with the protocol; - Pregnancy or lactation for female subjects of child-bearing potential (i.e., < two years post-menopausal or not surgically sterile); - For sexually active male subjects, unwillingness or incapability of using appropriate contraception methods; - Severe renal or hepatic impairment.

Study Design


Intervention

Drug:
Cromolyn
Active capsules for inhalation.
Other:
Placebo
Non-active capsules for inhalation.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
AZTherapies, Inc.

Outcome

Type Measure Description Time frame Safety issue
Primary Montreal Cognitive Assessment (MoCA) The primary endpoint is the difference in performance in the ALZT-OP1a adjuvant treatment group compared to the placebo group, as quantified by the mean change from baseline to Week 12 scored on MoCA. Baseline and Week 12
Secondary Mini Mental State Examination (MMSE) The secondary endpoint is the difference in performance in the ALZT-OP1a adjuvant treatment group compared to the placebo group, as quantified by the mean change from baseline to week 12 in points scored on MMSE. Baseline and Week 12
See also
  Status Clinical Trial Phase
Recruiting NCT05196659 - Collaborative Quality Improvement (C-QIP) Study N/A
Recruiting NCT06027788 - CTSN Embolic Protection Trial N/A
Completed NCT03281590 - Stroke and Cerebrovascular Diseases Registry
Recruiting NCT05518305 - Platelet Expression of FcγRIIa and Arterial Hemodynamics to Predict Recurrent Stroke in Intracranial Atherosclerosis
Recruiting NCT06029959 - Stroke and CPAP Outcome Study 3 N/A
Recruiting NCT03728738 - Zero Degree Head Positioning in Hyperacute Large Artery Ischemic Stroke Phase 3
Terminated NCT03396419 - IMPACT- 24col Collateral Blood Flow Assessment Following SPG Stimulation in Acute Ischemic Stroke (ImpACT-24B Sub-Study)
Recruiting NCT05065216 - Treatment of Acute Ischemic Stroke (ReMEDy2 Trial) Phase 2/Phase 3
Recruiting NCT04897334 - Transcranial Direct Current Stimulation and Rehabilitation to Ameliorate Impairments in Neurocognition After Stroke N/A
Not yet recruiting NCT06462599 - Osteopontin Gene Polymorphism in Stroke Patients in Egypt
Not yet recruiting NCT06026696 - Cohort of Neurovascular Diseases Treated in the Acute Phase and Followed at Lariboisière
Not yet recruiting NCT06032819 - Differentiating Between Brain Hemorrhage and Contrast
Recruiting NCT02910180 - Genetic, Metabolic, and Growth Factor Repository for Cerebrovascular Disorders
Completed NCT03554642 - Walkbot Robotic Training for Improvement in Gait Phase 3
Completed NCT02922452 - A Study to Evaluate the Effect of Diltiazem on the Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects Phase 1
Withdrawn NCT01866189 - Identification of Hypoxic Brain Tissues by F-MISO PET in Acute Ischemic Stroke N/A
Recruiting NCT03041753 - Reperfusion Injury After Stroke Study N/A
Completed NCT02549846 - AdminiStration of Statin On Acute Ischemic stRoke patienT Trial Phase 4
Completed NCT01678534 - Reparative Therapy in Acute Ischemic Stroke With Allogenic Mesenchymal Stem Cells From Adipose Tissue, Safety Assessment, a Randomised, Double Blind Placebo Controlled Single Center Pilot Clinical Trial Phase 2
Completed NCT02610803 - Paroxysmal Atrial Fibrillation in Patients With Acute Ischemic Stroke N/A